Brolucizumab Prevails in Treat-and-Extend Trial of Anti-VEGF Therapy for Eye Disease
MedPage Today) — NEW YORK CITY — The monoclonal antibody brolucizumab (Beovu) significantly extended the treatment-free interval without disease activity for neovascular age-related macula...